Drug Discovery & Pharmaceuticals

RSS

Study reveals CMPK-2 protein-coding gene as a potent inhibitor of flaviviruses

CMPK2 identified as a potential pan-flavivirus inhibitor, restricting virus replication and providing a basis for developing new antiviral treatments.

23 Apr 2023

Study should spur the development of alternative range of anti-TB inhibitors

Tuberculosis (TB) is one of the deadliest infectious diseases worldwide that is spread in the air like the common cold. TB is caused by the bacterium Mycobacterium tuberculosis (Mtb) and was responsible for approximately 1.6 million deaths in 2021.

20 Apr 2023

New drug could effectively disarm multidrug-resistant bacteria

A new type of drug could provide a way to treat multidrug-resistant bacteria, according to a study published in Nature Communications.

19 Apr 2023

New DCFHP-alum COVID-19 vaccine candidate shows durable, broad-spectrum protection in non-human primates

The newly developed DCFHP-alum COVID-19 vaccine candidate is affordable and effective for mass vaccination.

18 Apr 2023

New biologic inactivates potent opioid and reverses overdose

A new therapeutic designed by Scripps Research chemists can alter the molecular structure of the potent opioid carfentanil, inactivating the opioid and reversing a carfentanil overdose.

18 Apr 2023

Study offers novel insights into reducing adverse effects of antibiotics on the gut microbiome

Antibiotics help to fight bacterial infections, but they can also harm the helpful microbes living in the gut, which can have long-lasting health consequences.

17 Apr 2023

From Sanger Sequencing to the Human Genome Project: The Evolution of DNA Sequencing Technology

In this inspiring interview, we speak to Dr. Radoje Drmanac, co-founder of Complete Genomics, about the past, present, and future of genomics research.

From MGI 13 Apr 2023

New potential therapeutic developed for diffuse intrinsic pontine glioma using ASO technology

Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain cancer that often kills within a year of diagnosis. Surgery is almost impossible because of the tumors' location.

12 Apr 2023

Genetically-engineered probiotic could be a new way to reduce alcohol-induced health problems

Excessive alcohol consumption leads to painful hangovers and accompanying headaches, fatigue, and nausea.

11 Apr 2023

Chemists discover novel, highly effective anticancer agents with tridimensional structures

A research team co-led by chemists from City University of Hong Kong recently discovered novel, highly effective anticancer agents with tridimensional structures, which have high anticancer activity, low toxicity and the ability to overcome drug resistance in cancer cells.

7 Apr 2023

Nasal SARS-CoV-2 vaccine outperforms existing vaccines in preclinical trial

Researchers assess the role of the live-attenuated vaccine sCPD9 in inducing systemic and mucosal immunity against SARS-CoV-2 variants.

6 Apr 2023

Researchers construct super-sized nanocage for delivering larger drug cargoes

Think about how frustrating it is to try to fit a gift into a box that is too small. Sometimes you just need a bigger box.

6 Apr 2023

Seda: Winners of Bionow Business Growth Award 2022

Seda are honoured to have been named winners of the Business Growth Award at the prestigious Bionow Awards 2022. This award recognises our outstanding growth, innovation, and contribution to the North of England’s life sciences sector, as well as our commitment to innovation and excellence in the pharmaceutical industry.

From Seda Pharmaceutical Development Services 6 Apr 2023

New anticancer agent activated by ultrasound waves does not have strong side effects

Chemotherapy treatments produce strong side effects. A new agent that accumulates in the tumor tissue and is activated thereby ultrasound waves does not have this problem.

5 Apr 2023

Mosaic Therapeutics closes $28m series A funding and appoints Brian Gladsden as CEO

Mosaic Therapeutics, an oncology therapeutics company dedicated to resolving cancer’s complexity to power new treatments for patients, today announced the close of its $28 million series A funding round.

From Mosaic Therapeutics 4 Apr 2023

Live attenuated nasal vaccine elicits superior immunity to SARS-CoV-2 variants in hamsters

Since the beginning of the COVID-19 pandemic, researchers have been working on mucosal vaccines that can be administered through the nose.

4 Apr 2023

N-abling the acceleration of the life sciences through precision dispensing

In this interview, we speak to Holger Eickhoff, CEO and Founder of Scienion, about their latest technology, The Nucleus Automation Ecosystem.

From SCIENION GmbH 4 Apr 2023

Optibrium appoints computational modelling expert, Dr Hamed Tabatabaei Ghomi as Head of Research

Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the appointment of Dr Hamed Tabatabaei Ghomi as Head of Research.

From Optibrium Ltd. 4 Apr 2023

MIP Discovery announces drugs of abuse reagent launch

MIP Discovery, a leader in rationally designed detection reagents based on its proprietary nanoMIP technology, in response to the growing synthetic opioid crisis has announced the launch of its first drugs of abuse products which are able to recognize norfentanyl, the main urinary metabolite of fentanyl.

From MIP Discovery 4 Apr 2023

Overcoming challenges in flavivirus vaccine development: Exploring modern vaccine types for Dengue, Zika, and beyond

Researchers discuss the challenges impeding the development of vaccines against flaviviruses.